ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE


Year of Award:
2005
Award Type:
R43
Project Number:
CA114126
RFA Number:
RFA-CA-05-006
Technology Track:
Molecular & Cellular Analysis Technologies
PI/Project Leader:
LIM, MARK
Other PI or Project Leader:
N/A
Institution:
AMBERGEN, INC
Significant advances have been made in the development of a new generation of molecularly targeted cancer drugs, many of which are only now emerging from the drug development pipeline. Examples of small molecule drugs are imatinib (Gleevec), used to treat